A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

NCT06195228 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

800

Enrollment

OTHER

Sponsor class

Conditions

Advanced Thyroid Cancer Patients Who Received Target Therapy

Interventions

DRUG: dabrafenib plus trametinib with or without PD-1 antibody
DRUG: entrectinib or larotrectinib with or without anti-PD-1 antibdoy
DRUG: pralsetinib or selpercatinib with or without anti-PD-1 antibdoy
DRUG: anlotinib or anlotinib plus anti-PD-1 antibody
DRUG: lenvatinib plus anti-PD-1 antibody
DRUG: Other Targets: precise treatment based on the target

Sponsor

Fudan University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]